Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
9.72
+0.37 (3.96%)
At close: Sep 12, 2025, 4:00 PM EDT
9.79
+0.07 (0.72%)
After-hours: Sep 12, 2025, 6:10 PM EDT
Verastem Employees
Verastem had 78 employees as of December 31, 2024. The number of employees increased by 5 or 6.85% compared to the previous year.
Employees
78
Change (1Y)
5
Growth (1Y)
6.85%
Revenue / Employee
$27,397
Profits / Employee
-$2,135,321
Market Cap
598.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | 48 | -87 | -64.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VSTM News
- 16 days ago - Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer - Business Wire
- 4 weeks ago - Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 6 weeks ago - Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 7 weeks ago - Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer - Business Wire
- 2 months ago - Verastem: The Market Is Ignoring The Progress - Seeking Alpha
- 2 months ago - Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Business Wire